Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
The Long-term Survival of a Patient with Adenosquamous Lung Carcinoma Harboring EGFR-activating Mutations Who was Treated with Gefitinib
Kentaro IwanagaNaoko Sueoka-AraganeTomomi NakamuraDaisuke MoriShinya Kimura
Author information
JOURNAL OPEN ACCESS

2012 Volume 51 Issue 19 Pages 2771-2774

Details
Abstract

A 56-year-old woman diagnosed with squamous cell lung carcinoma after a transbronchoscopic examination underwent left upper lobectomy, which revealed a pathological diagnosis of adenosquamous carcinoma containing moderately differentiated squamous cell carcinoma and bronchioloalveolar carcinoma. The epidermal growth factor receptor (EGFR) exon 19 delE746-A750 mutation was detected in deoxyribonucleic acid (DNA) isolated from specimens of both components using microdissection. Treatment with the EGFR tyrosine kinase inhibitor, gefitinib, resulted in a long-term tumor response lasting three years. Adenosquamous carcinoma is difficult to diagnose using transbronchoscopic procedures. Therefore, the examination of EGFR mutation status is important in order to determine the appropriate treatment, even in patients with non-adenocarcinoma.

Information related to the author
© 2012 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top